These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21428178)

  • 1. Changes in plasma levels of MMP-9, MMP-7 and their inhibitors in patients with coronary artery disease.
    Crăciunescu I; Serban M; Iancu M; Revnic C; Muraru D; Alexandru D; Rogoz D; Popescu BA; Ginghină C
    Rom J Intern Med; 2010; 48(2):141-9. PubMed ID: 21428178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of matrix metalloproteinases (MMP2, MMP7 and MMP9) genetic variants with left ventricular dysfunction in coronary artery disease patients.
    Mishra A; Srivastava A; Mittal T; Garg N; Mittal B
    Clin Chim Acta; 2012 Oct; 413(19-20):1668-74. PubMed ID: 22664146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Plasma matrix metalloproteinases-2 and -9 levels are elevated in patients with acute coronary syndrome and coronary chronic total occlusion].
    Tang QD; Wu PS; Hou YQ; Huang Z; Zhou ZJ; Guo ZG; Xiu JC; Wang YG
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 May; 29(5):1004-7. PubMed ID: 19460733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation.
    Tayebjee MH; Nadar SK; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):770-4. PubMed ID: 15363818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
    Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
    Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure.
    Yan AT; Yan RT; Spinale FG; Afzal R; Gunasinghe HR; Arnold M; Demers C; McKelvie RS; Liu PP
    J Card Fail; 2006 Sep; 12(7):514-9. PubMed ID: 16952784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers.
    Giansante C; Fiotti N; Di Chiara A; Altamura N; Wasserman S; Fioretti P; Guarnieri G
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):602-7. PubMed ID: 17667031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MMP/TIMP imbalance in amniotic fluid during PROM: an indirect support for endogenous pathway to membrane rupture.
    Fortunato SJ; Menon R; Lombardi SJ
    J Perinat Med; 1999; 27(5):362-8. PubMed ID: 10642956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study.
    Kelly D; Cockerill G; Ng LL; Thompson M; Khan S; Samani NJ; Squire IB
    Eur Heart J; 2007 Mar; 28(6):711-8. PubMed ID: 17339265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
    Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
    Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart.
    Soini Y; Satta J; Määttä M; Autio-Harmainen H
    J Pathol; 2001 Jun; 194(2):225-31. PubMed ID: 11400152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction.
    Yasuda S; Miyazaki S; Kinoshita H; Nagaya N; Kanda M; Goto Y; Nonogi H
    Clin Sci (Lond); 2007 Jan; 112(1):43-9. PubMed ID: 16939410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of matrix metalloproteinases activity in acute myocardial infarction.
    Papadopoulos DP; Moyssakis I; Makris TK; Poulakou M; Stavroulakis G; Perrea D; Votteas VE
    Eur Cytokine Netw; 2005 Jun; 16(2):152-60. PubMed ID: 15941687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
    Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
    Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty.
    Kuliczkowski W; Urbaniak J; Hallén J; Woźniak M; Poloński L; Mysiak A; Atar D; Zembala M; Serebruany V
    Kardiol Pol; 2013; 71(5):453-63. PubMed ID: 23788085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The assessment of left ventricular twist in anterior wall myocardial infarction using two-dimensional speckle tracking imaging.
    Takeuchi M; Nishikage T; Nakai H; Kokumai M; Otani S; Lang RM
    J Am Soc Echocardiogr; 2007 Jan; 20(1):36-44. PubMed ID: 17218200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between hematologic parameters and left ventricular systolic dysfunction in stable patients with multi-vessel coronary artery disease.
    Doğdu O; Akpek M; Yarlıoğlueş M; Kalay N; Ardıç I; Elçik D; Senarslan O; Kaya MG
    Turk Kardiyol Dern Ars; 2012 Dec; 40(8):706-13. PubMed ID: 23518885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic value of symptoms and signs of advanced heart failure and low left ventricle ejection fraction in patients after myocardial infarction with chronic heart failure].
    Kuch M; Janiszewski M; Janiszewski M; Braksator W; Mamcarz A; Sadkowska K; Kuch J; Dłuzniewski M
    Pol Merkur Lekarski; 2006 Mar; 20(117):285-8. PubMed ID: 16780256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
    Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z
    Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.